DIA: Driving Insights to Action
Science:Life Sciences
New drugs are getting through the FDA approval process faster. According to a study published in January 2020, the review time for standard drug applications has decreased from more than 36 months in 1983 to approximately ten months in 2018. “It can be a good thing for drugs to reach the market faster, if those drugs offer large benefits. But often drugs offer only very small benefits over existing treatments,” says Dr. Jonathan Darrow, pharmaceutical policy expert and Assistant Professor at Harvard Medical School in Boston. “The system we have is a patchwork of various policies,” explains Dr. Joshua Sharfstein, former FDA Principal Deputy Commissioner, now Vice Dean and Professor at Johns Hopkins Bloomberg School of Public Health in Baltimore. “We should take a step back and say, ‘Are there ways to align incentives more so we have more money to spend for treatments that make a huge difference for people who need them?’”
DIA 2016 Co-Chair: "A Market for Ideas" in a Global Forum
Advances and Best Practices in Communications with Consumers and Health Care Professionals
Challenges in Deploying a Global Pharmacovigilance System
Challenges in Adverse Event Reporting and the Role of Specialty Pharmacies
Access & Attitude to Clinical Trial Technology: The Global Investigator Perspective
What Precision Medicine Means Today and Will Mean Tomorrow for Patient Care
FDA Director of Division of Online Communications, CDER, Discusses FDA's First Mobile App
Pediatric Drug Development & Therapeutics in September TIRS
TransCelerate BioPharma Clinical Quality Management System Conceptual Framework
Patient Engagement and Rare Diseases at DIA
Ethical Considerations in Policies on Drug, Device, and Companion Diagnostics Development
Medical Communications Transformation and Impact on Health Care Community
Challenging the Value of Source Data Verification
The Impact of Collaborative and Risk Sharing Innovation Approaches on Clinical and Regulatory Cycle Times
How to Get Published with DIA
Perspectives on Statistics
An Expanded Role for Patients in Clinical Trial Design
Women and Children First—Time for a Coalition to Address a Substantial Patient Need
PhactMI Strives to Bring Medical Information Transparency to the Health Care Community
Clinical Safety and Pharmacovigilance
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology